diethylcarbamazine has been researched along with Itching in 15 studies
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double-blind controlled clinical trial comparing the safety and efficacy of oral diethylcarbamazine citrate (DEC) with topical DEC for the treatment of onchocerciasis twenty men with moderate skin-snip microfilarial counts received daily therapy for 1 week, then weekly therapy for the rest of 6 months." | 9.05 | Controlled clinical trial of oral and topical diethylcarbamazine in treatment of onchocerciasis. ( Greene, BM; Langham, ME; Taylor, HR, 1980) |
| "Flubendazole, an injectable benzimidazole drug, was compared with diethylcarbamazine (DEC) in a prospective double-blind study of the treatment of onchocerciasis." | 9.05 | Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. ( Beltran-Hernandez, F; Dominguez-Vazquez, A; Greene, BM; Murphy, RP; Rivas-Alcala, AR; Ruvalcaba-Macias, AM; Taylor, HR, 1983) |
| "One hundred patients with onchocerciasis were treated with diethylcarbamazine: a single course of treatment led to clinical cure in 48% of the patients; no means of anticipating which patients might require only a single course of treatment was found." | 7.65 | Onchocerciasis treated with diethylcarbamazine. ( Rée, GH, 1977) |
| " Clinical adverse reactions were recorded in four ivermectin, ten DEC and three placebo patients." | 6.66 | A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis. ( Aziz, MA; Badiane, S; Diallo, JS; Diallo, S; Diop-Mar, I; Gaxotte, P; Lariviere, M; N'Dir, O; Py, D; Schulz-Key, H, 1986) |
| "Hypotension, fever, adenitis and pruritus were all correlated with infection intensity in these patients while arthralgia and tachycardia were not." | 5.27 | The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. ( Awadzi, K; Francis, H; Ottesen, EA, 1985) |
| "In a double-blind controlled clinical trial comparing the safety and efficacy of oral diethylcarbamazine citrate (DEC) with topical DEC for the treatment of onchocerciasis twenty men with moderate skin-snip microfilarial counts received daily therapy for 1 week, then weekly therapy for the rest of 6 months." | 5.05 | Controlled clinical trial of oral and topical diethylcarbamazine in treatment of onchocerciasis. ( Greene, BM; Langham, ME; Taylor, HR, 1980) |
| "Flubendazole, an injectable benzimidazole drug, was compared with diethylcarbamazine (DEC) in a prospective double-blind study of the treatment of onchocerciasis." | 5.05 | Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis. ( Beltran-Hernandez, F; Dominguez-Vazquez, A; Greene, BM; Murphy, RP; Rivas-Alcala, AR; Ruvalcaba-Macias, AM; Taylor, HR, 1983) |
| "In the last ten years ivermectin appeared an efficient and safe alternative to diethylcarbamazine which is known to induce severe adverse reactions in loiasis, including encephalitis." | 3.69 | [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin]. ( Boussinesq, M; Chippaux, JP; Ducorps, M; Gardon, J; Gardon-Wendel, N; Ndong, W; Ranque, S; Schneider, D, 1995) |
| "One hundred patients with onchocerciasis were treated with diethylcarbamazine: a single course of treatment led to clinical cure in 48% of the patients; no means of anticipating which patients might require only a single course of treatment was found." | 3.65 | Onchocerciasis treated with diethylcarbamazine. ( Rée, GH, 1977) |
| " Clinical adverse reactions were recorded in four ivermectin, ten DEC and three placebo patients." | 2.66 | A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis. ( Aziz, MA; Badiane, S; Diallo, JS; Diallo, S; Diop-Mar, I; Gaxotte, P; Lariviere, M; N'Dir, O; Py, D; Schulz-Key, H, 1986) |
| "Lymphangitis has not recurred." | 1.28 | Observations on the clinical manifestations and treatment of an experimental infection with Brugia malayi in man. ( Chen, YN; Fang, Z; Liu, JY; Tu, ZP; Wang, GQ, 1989) |
| "Hypotension, fever, adenitis and pruritus were all correlated with infection intensity in these patients while arthralgia and tachycardia were not." | 1.27 | The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. ( Awadzi, K; Francis, H; Ottesen, EA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (86.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dunn, CL | 1 |
| Dunn, CP | 1 |
| Ayars, AG | 1 |
| Taylor, HR | 3 |
| Greene, BM | 3 |
| Langham, ME | 1 |
| Dominguez-Vazquez, A | 1 |
| Ruvalcaba-Macias, AM | 1 |
| Rivas-Alcala, AR | 1 |
| Murphy, RP | 1 |
| Beltran-Hernandez, F | 1 |
| Rozenman, D | 1 |
| Kremer, M | 1 |
| Zuckerman, F | 1 |
| Bianco, AE | 1 |
| Denham, DA | 1 |
| Awadzi, K | 3 |
| Orme, ML | 2 |
| Breckenridge, AM | 2 |
| Gilles, HM | 2 |
| Brown, EJ | 1 |
| Humphrey, RL | 1 |
| Lawley, TJ | 1 |
| Ducorps, M | 1 |
| Gardon-Wendel, N | 1 |
| Ranque, S | 1 |
| Ndong, W | 1 |
| Boussinesq, M | 1 |
| Gardon, J | 1 |
| Schneider, D | 1 |
| Chippaux, JP | 1 |
| Hutchinson, DB | 1 |
| El-Sheikh, H | 1 |
| Jones, BR | 1 |
| Anderson, J | 1 |
| Fuglsang, H | 1 |
| Mackenzie, CD | 1 |
| Rée, GH | 1 |
| Liu, JY | 1 |
| Wang, GQ | 1 |
| Chen, YN | 1 |
| Tu, ZP | 1 |
| Fang, Z | 1 |
| Diallo, S | 1 |
| Aziz, MA | 1 |
| Lariviere, M | 1 |
| Diallo, JS | 1 |
| Diop-Mar, I | 1 |
| N'Dir, O | 1 |
| Badiane, S | 1 |
| Py, D | 1 |
| Schulz-Key, H | 1 |
| Gaxotte, P | 1 |
| Francis, H | 1 |
| Ottesen, EA | 1 |
| Tejan-Jalloh, II | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire[NCT02845713] | Phase 1 | 66 participants (Actual) | Interventional | 2016-04-17 | Completed | ||
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
6 trials available for diethylcarbamazine and Itching
| Article | Year |
|---|---|
Controlled clinical trial of oral and topical diethylcarbamazine in treatment of onchocerciasis.
Topics: Administration, Oral; Administration, Topical; Clinical Trials as Topic; Diethylcarbamazine; Double- | 1980 |
Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis.
Topics: Adolescent; Adult; Antinematodal Agents; Benzimidazoles; Child; Clinical Trials as Topic; Diethylcar | 1983 |
The chemotherapy of onchocerciasis VI. The effect of indomethacin and cyproheptadine on the Mazzotti reaction.
Topics: Adult; Clinical Trials as Topic; Cyproheptadine; Diethylcarbamazine; Double-Blind Method; Humans; Hy | 1982 |
The chemotherapy of onchocerciasis VII. The effect of prednisone on the Mazzotti reaction.
Topics: Adult; Clinical Trials as Topic; Diethylcarbamazine; Double-Blind Method; Fever; Humans; Hypotension | 1982 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
A double-blind comparison of the efficacy and safety of ivermectin and diethylcarbamazine in a placebo controlled study of Senegalese patients with onchocerciasis.
Topics: Adolescent; Adult; Clinical Trials as Topic; Diethylcarbamazine; Double-Blind Method; Eye Diseases; | 1986 |
9 other studies available for diethylcarbamazine and Itching
| Article | Year |
|---|---|
When long-standing hives are not chronic spontaneous urticaria.
Topics: Chronic Disease; Dermatitis; Diagnosis, Differential; Diethylcarbamazine; Exanthema; Filaricides; Hu | 2021 |
Onchocerciasis in Israel.
Topics: Adolescent; Diagnosis, Differential; Diethylcarbamazine; Ethiopia; Eye Diseases; Humans; Israel; Mal | 1984 |
The action of diethylcarbamazine on the skin-dwelling microfilariae of Monanema globulosa (Nematoda: Filarioidea) in rodents.
Topics: Animals; Diethylcarbamazine; Disease Models, Animal; Female; Filariasis; Filarioidea; Gerbillinae; G | 1984 |
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Topics: Adult; Aged; Animals; Arthralgia; C-Reactive Protein; Cameroon; Diethylcarbamazine; Female; Fever; F | 1995 |
Adverse reactions to cutaneous diethylcarbamazine in onchocerciasis.
Topics: Diethylcarbamazine; Drug Hypersensitivity; Humans; Onchocerciasis; Pruritus | 1979 |
Onchocerciasis treated with diethylcarbamazine.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Diethylcarbamazine; Female; Humans; Male; Middle A | 1977 |
Observations on the clinical manifestations and treatment of an experimental infection with Brugia malayi in man.
Topics: Animals; Brugia; Culicidae; Diethylcarbamazine; Elephantiasis, Filarial; Eosinophils; Filariasis; Hu | 1989 |
The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity.
Topics: Adolescent; Adult; Arthritis; Diethylcarbamazine; Fever; Humans; Leukocyte Count; Liver; Lymphadenit | 1985 |
Some observations on onchocerciasis in the Koinadugu District of Sierra Leone.
Topics: Corneal Opacity; Deafness; Diethylcarbamazine; Hernia, Inguinal; Humans; Keratitis; Male; Onchocerci | 1974 |